QPS Blog
Featuring news and insights on QPS’ and its Clients’ efforts in providing patients with novel, safe, effective and affordable medicines
Dr. Diane Krieger from QPS MRA acknowledged in NEJM for her role as investigator in the SCALE Obesity and Prediabetes Study Group
dateJuly 27, 2015
dateAbby Doppler, QPS Marketing

The sheer abundance of diet drugs available suggests two things: 1) there is a huge market for them and 2) none of them work significantly better than the rest (if at all.) Imagine the excitement, then, at finding that an agent already prescribed for diabetes really can help patients lose significant amounts of weight. And QPS MRA’s own Dr. Krieger had a hand in developing the results!

Read the original publication in the New England Journal of Medicine (NEJM): “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management,” supported by Novo Nordisk.

The shorthand version:

In a 56-week, double-blind trial, 3731 overweight, non-diabetic patients received once-daily 3.0 mg subcutaneous injections of liraglutide (aka Victoza™) or placebo, plus lifestyle modification counseling. Results are summarized as follows.

  Liraglutide Placebo
Number of pts 2487 1244
Average wt. loss 8.4 kg 2.8 kg
Lost > 5% body wt. 63% 27%
Lost > 10%body wt. 33% 11%

The most frequent side effects were mild-moderate nausea and diarrhea. Serious adverse events occurred in 6% of the liraglutide patients and 5% of the placebo group.